Halozyme Therapeutics, Inc. (HALO): Bullish On Halozyme: Short-Term ... Seeking Alpha The second therapy is MabThera SC, or Rituximab, with trade name Rituxan. Rituxan was approved in the US in 1997 for the treatment of non-Hodgkin's lymphoma. With validation of the approval of the monoclonal antibody Herceptin SC, it's looking like ... |
